WallStSmart

Apogee Therapeutics, Inc. Common Stock (APGE)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

APGE leads profitability with a 0.0% profit margin vs -210.5%. INSM earns a higher WallStSmart Score of 39/100 (F).

APGE

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 10.55

INSM

Hold

39

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APGE1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
10.5510/10

Safe zone — low bankruptcy risk

INSM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
152.6%10/10

Revenue surging 152.6% year-over-year

Areas to Watch

APGE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

INSM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
40.3x2/10

Trading at 40.3x book value

Return on EquityProfitability
-249.3%2/10

ROE of -249.3% — below average capital efficiency

Free Cash FlowQuality
$-294.19M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : APGE

The strongest argument for APGE centers on Altman Z-Score.

Bull Case : INSM

The strongest argument for INSM centers on Revenue Growth. Revenue growth of 152.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : APGE

The primary concerns for APGE are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are EPS Growth, Price/Book, Return on Equity.

Key Dynamics to Monitor

APGE profiles as a value stock while INSM is a hypergrowth play — different risk/reward profiles.

APGE carries more volatility with a beta of 1.40 — expect wider price swings.

INSM is growing revenue faster at 152.6% — sustainability is the question.

APGE generates stronger free cash flow (-63M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 25/100) and 152.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apogee Therapeutics, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?